Incidence and Predictors of Clinical Outcomes in Real‐Life Patients With Atrial Fibrillation Treated With Oral Factor Xa Inhibitors: The Follow‐Up Results of the ANATOLIA‐AF Study
Clinical Cardiology · 2025
DOI: 10.1002/clc.70088 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Cardiology, 2025. Verfasst von Umut Kocabaş und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Başkent University Izmir Hospital, Izmir, Türkiye. Hauptthemen laut MEDLINE: Factor Xa Inhibitors, Atrial Fibrillation, Ischemic Stroke, Stroke. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
The main objective of this study is to determine the incidence and predictors of clinical outcomes in patients with AF treated with factor Xa inhibitors in a real‐world setting.
Methods
The present study was a multicentre and observational study that included patients with AF who were treated with factor Xa inhibitors. The primary outcome was the composite of ischemic stroke, TIA, systemic embolism, major bleeding, and all‐cause mortality.
Results
A total of 1162 patients from 26 cardiology centers were included in this study, with a median age of 72 years. During the median 12‐month follow‐up period, the primary outcome occurred in 195 patients (16.8%). Treatment with rivaroxaban compared with apixaban and edoxaban showed a lower rate of ischemic stroke, TIA, and/or systemic embolism (2.2% vs. 4.7% vs. 6.5%, respectively, p = 0.014). The major bleeding rate was similar between all three factor Xa inhibitors. The all‐cause mortality rate in the rivaroxaban group was lower compared with the apixaban and edoxaban groups (9.8% vs. 15.1% vs. 12.4%, respectively, p = 0.042). Overall, the frequency of primary outcome was 13.8%, 19.6%, and 20.6% for patients treated with rivaroxaban, apixaban, and edoxaban, respectively ( p = 0.019). Older age, male sex, low body weight, high bleeding risk, heart failure, hypertension, liver failure, and treatment with apixaban 2.5 mg b.i.d. were independently associated with the development of primary outcome.
Conclusion
The follow‐up data from the ANATOLIA‐AF study provides detailed data about the incidence and independent predictors of adverse clinical outcomes in patients with AF treated with factor Xa inhibitor treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Başkent University Izmir Hospital, Izmir, Türkiye.
- Department of Public Health, Faculty of Medicine, Ege University, Izmir, Türkiye.
- Department of Cardiology, Akhisar State Hospital, Manisa, Türkiye.
- Department of Cardiology, Faculty of Medicine, Eskişehir Osmangazi University, Eskişehir, Türkiye.
- Department of Cardiology, Manisa City Hospital, Manisa, Türkiye.
- Department of Cardiology, Ağrı Training and Research Hospital, Ağrı, Türkiye.
Zitieren
APA
Kocabaş, U., Ergin, I., Sönmez, S. C., Yavuz, V., Murat, S., Özdemir, I. H., Genç, Ö., Tüner, H., Meriç, B. K., Aslan, O., Dal, A., Taşkın, U., Şen, T., İbişoğlu, E., Erdoğan, A., Özgeyik, M., Demir, M., Urgun, Ö. D., Doğduş, M., …, & Kıvrak, T. (2025). Incidence and Predictors of Clinical Outcomes in Real‐Life Patients With Atrial Fibrillation Treated With Oral Factor Xa Inhibitors: The Follow‐Up Results of the ANATOLIA‐AF Study. Clinical Cardiology. https://doi.org/10.1002/clc.70088
Vancouver
Kocabaş U, Ergin I, Sönmez SC, Yavuz V, Murat S, Özdemir IH, et al. Incidence and Predictors of Clinical Outcomes in Real‐Life Patients With Atrial Fibrillation Treated With Oral Factor Xa Inhibitors: The Follow‐Up Results of the ANATOLIA‐AF Study. Clinical Cardiology. 2025. doi:10.1002/clc.70088
BibTeX
@article{Kocaba2025,
author = {Kocabaş, Umut and Ergin, Isil and Sönmez, Sadi Can and Yavuz, Veysel and Murat, Selda and Özdemir, Ibrahim Halil and Genç, Ömer and Tüner, Haşim and Meriç, Bengisu Keskin and Aslan, Onur and Dal, Ahmet and Taşkın, Uğur and Şen, Taner and İbişoğlu, Ersin and Erdoğan, Aslan and Özgeyik, Mehmet and Demir, Mevlüt and Urgun, Örsan Deniz and Doğduş, Mustafa and Çakal, Sinem and Çayırlı, Sercan and Güler, Arda and Karabulut, Dilay and Dalgıç, Onur and Murat, Bektaş and Karabulut, Umut and Öztekin, Gülsüm Meral Yılmaz and Biter, Halil İbrahim and Sinan, Ümit Yaşar and Barış, Veysel Özgür and Kaplan, Mehmet and Altın, Cihan and Kıvrak, Tarık},
title = {Incidence and Predictors of Clinical Outcomes in Real‐Life Patients With Atrial Fibrillation Treated With Oral Factor Xa Inhibitors: The Follow‐Up Results of the ANATOLIA‐AF Study},
journal = {Clinical Cardiology},
year = {2025},
doi = {10.1002/clc.70088}
}
EUVIMED